logo-loader
viewCaladrius Biosciences Inc

Caladrius Biosciences CEO outlines key objectives for its cardiovascular programs in 2020

Caladrius Biosciences, Inc (NASDAQ:CLBS) CEO David J. Mazzo, PhD sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The New Jersey-based late-stage therapeutics development company's current product candidates include three developmental treatments for cardiovascular diseases.

Quick facts: Caladrius Biosciences Inc

Price: 3.19 USD

NASDAQ:CLBS
Market: NASDAQ
Market Cap: $33.18 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

3 hours, 7 minutes ago

2 min read